Cancer Drug Trial
Cancer Drug Trial
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong....
Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial
Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML)...
Zantrene Highly Effective in a Mouse Model of Extramedullary AML
Race CEO Phil Lynch Talks with Proactive at the ASX Small and Mid-Cap Conference
Race Oncology ASX Small and Mid Cap Conference Presentation
Compelling Preclinical Kidney Cancer Results for Zantrene
MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene
MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene
23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a...
Appointment of Chief Financial Officer
Appointment of Chief Financial Officer
31 January 2022 – Race Oncology Limited (“Race”) is pleased to announce theappointment of Christina Manfre, as Chief Financial Officer. Christina is employed as a partner at PKF Sydney Pty Ltd and will via...
New Independent Study Identifies Activity of Zantrene in Type 2 Diabetes
New Independent Study Identifies Activity of Zantrene in Type 2 Diabetes
25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details of a recent independent scientific publication in the journal Cells, confirming Zantrene® (bisantrene dihydrochloride) is a highly effective inhibitor...
